These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18418705)

  • 1. ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A-B-C ? : editorial to: effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.
    de Boer RA; van Veldhuisen DJ
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):261-3. PubMed ID: 18418705
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
    Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN).
    Remme WJ; Riegger G; Hildebrandt P; Komajda M; Jaarsma W; Bobbio M; Soler-Soler J; Scherhag A; Lutiger B; Rydén L
    Cardiovasc Drugs Ther; 2004 Jan; 18(1):57-66. PubMed ID: 15115904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
    Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
    Fujimura M; Akaike M; Iwase T; Yoshida S; Sumitomo Y; Yagi S; Ikeda Y; Hashizume S; Aihara K; Nishiuchi T; Yasumura Y; Matsumoto T
    Acta Cardiol; 2009 Oct; 64(5):589-95. PubMed ID: 20058503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary 8-hydroxy-2'-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure.
    Susa T; Kobayashi S; Tanaka T; Murakami W; Akashi S; Kunitsugu I; Okuda S; Doi M; Wada Y; Nao T; Yamada J; Ueyama T; Okamura T; Yano M; Matsuzaki M
    Circ J; 2012; 76(1):117-26. PubMed ID: 22008315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
    Remme WJ
    Cardiol Clin; 2007 Nov; 25(4):581-94; vii. PubMed ID: 18063162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol.
    Nessler J; Nessler B; Kitliński M; Stepniewski M; Piwowarska W
    Cardiol J; 2008; 15(4):329-37. PubMed ID: 18698541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure EvaluatioN trial (CARMEN)--rationale and design.
    Remme WJ;
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):69-77. PubMed ID: 11504166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
    Fragasso G; Spoladore R; Maranta F; Corti A; Lattuada G; Colombo B; Locatelli M; Salerno A; Calori G; Briceno L; Alfieri AB; Perseghin G; Margonato A
    J Cardiovasc Med (Hagerstown); 2013 Jan; 14(1):49-56. PubMed ID: 23018486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
    Gundogdu F; Bozkurt E; Kiziltunc A; Sevimli S; Arslan S; Gurlertop Y; Senocak H; Karakelleoglu S
    Echocardiography; 2007 Feb; 24(2):113-7. PubMed ID: 17313541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dismantling mandates in the treatment of heart failure.
    Leier CV
    J Am Coll Cardiol; 2004 Nov; 44(9):1831-3. PubMed ID: 15519015
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy.
    Botoni FA; Poole-Wilson PA; Ribeiro AL; Okonko DO; Oliveira BM; Pinto AS; Teixeira MM; Teixeira AL; Reis AM; Dantas JB; Ferreira CS; Tavares WC; Rocha MO
    Am Heart J; 2007 Apr; 153(4):544.e1-8. PubMed ID: 17383291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
    Richards AM; Doughty R; Nicholls MG; MacMahon S; Sharpe N; Murphy J; Espiner EA; Frampton C; Yandle TG;
    J Am Coll Cardiol; 2001 Jun; 37(7):1781-7. PubMed ID: 11401111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
    Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
    Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
    McMurray J; Cohen-Solal A; Dietz R; Eichhorn E; Erhardt L; Hobbs FD; Krum H; Maggioni A; McKelvie RS; Piña IL; Soler-Soler J; Swedberg K
    Eur J Heart Fail; 2005 Aug; 7(5):710-21. PubMed ID: 16087129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart failure therapy in evolution.
    Chatterjee K
    Circulation; 1996 Dec; 94(11):2689-93. PubMed ID: 8941088
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
    J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
    Heitmann M; Davidsen U; Stokholm KH; Rasmussen K; Burchardt H; Petersen EB
    Scand J Clin Lab Invest; 2002; 62(2):97-104. PubMed ID: 12004934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.